Atacand (correction)
Executive Summary
In a story on the supplemental approval of AstraZeneca's angiotensin receptor blocker Atacand, the statement "I am just a bit concerned by the proposed labeling that I have seen....[It] seems to leave that door open, and once a door like that is open, it's going to be their job to walk through it and encourage people to use it that way" was incorrectly attributed to FDA Office of Drug Evaluation I Director Robert Temple (1"The Pink Sheet" Feb. 28, 2004, p. 3). The statement was made by Cardiovascular & Renal Drugs Advisory Committee member John Teerlink...
You may also be interested in...
Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure
AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.